August 24, 2017
Karo Pharma to buy Weifa for €138M
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.
Pharmaceuticals, Biotechnology and Life Sciences
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.